Annual EBITDA:
-$276.92M+$365.00K(+0.13%)Summary
- As of today, PACB annual EBITDA is -$276.92 million, with the most recent change of +$365.00 thousand (+0.13%) on December 31, 2024.
- During the last 3 years, PACB annual EBITDA has fallen by -$26.16 million (-10.43%).
- PACB annual EBITDA is now -810.52% below its all-time high of $38.97 million, reached on December 31, 2020.
Performance
PACB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
N/ASummary
- PACB quarterly EBITDA is not available.
Performance
PACB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Range
Earnings dates
TTM EBITDA:
N/ASummary
- PACB TTM EBITDA is not available.
Performance
PACB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PACB EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +0.1% | - | - |
| 3Y3 Years | -10.4% | - | - |
| 5Y5 Years | -286.9% | - | - |
PACB EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -10.4% | +1.9% | ||||
| 5Y | 5-Year | -810.5% | +1.9% | ||||
| All-Time | All-Time | -810.5% | +1.9% |
PACB EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | -$18.41M(+66.0%) | -$164.97M(+16.2%) |
| Mar 2025 | - | -$54.21M(-3.8%) | -$196.88M(+7.2%) |
| Dec 2024 | -$276.92M(+0.1%) | -$52.24M(-30.3%) | -$212.09M(+7.1%) |
| Sep 2024 | - | -$40.11M(+20.3%) | -$228.38M(+11.0%) |
| Jun 2024 | - | -$50.33M(+27.5%) | -$256.61M(+5.9%) |
| Mar 2024 | - | -$69.42M(-1.3%) | -$272.61M(+1.8%) |
| Dec 2023 | -$277.28M(+1.8%) | -$68.53M(-0.3%) | -$277.67M(+3.3%) |
| Sep 2023 | - | -$68.33M(-3.0%) | -$287.09M(-0.8%) |
| Jun 2023 | - | -$66.34M(+10.9%) | -$284.78M(+1.0%) |
| Mar 2023 | - | -$74.48M(+4.4%) | -$287.59M(-0.0%) |
| Dec 2022 | -$282.24M(-12.6%) | -$77.94M(-18.0%) | -$287.50M(-7.0%) |
| Sep 2022 | - | -$66.03M(+4.5%) | -$268.60M(-10.3%) |
| Jun 2022 | - | -$69.14M(+7.1%) | -$243.62M(-16.2%) |
| Mar 2022 | - | -$74.39M(-26.0%) | -$209.66M(-25.9%) |
| Dec 2021 | -$250.76M(-743.4%) | -$59.05M(-43.9%) | -$166.58M(-29.0%) |
| Sep 2021 | - | -$41.04M(-16.7%) | -$129.16M(-17.4%) |
| Jun 2021 | - | -$35.18M(-12.3%) | -$109.98M(-14.5%) |
| Mar 2021 | - | -$31.31M(-44.8%) | -$96.05M(-1.0%) |
| Dec 2020 | $38.97M(+154.5%) | -$21.63M(+1.1%) | -$95.08M(-7.0%) |
| Sep 2020 | - | -$21.86M(-2.9%) | -$88.86M(+4.0%) |
| Jun 2020 | - | -$21.25M(+30.0%) | -$92.55M(+0.8%) |
| Mar 2020 | - | -$30.34M(-97.0%) | -$93.25M(-2.9%) |
| Dec 2019 | -$71.58M(+23.0%) | -$15.41M(+39.7%) | -$90.60M(+12.9%) |
| Sep 2019 | - | -$25.55M(-16.4%) | -$104.03M(-2.7%) |
| Jun 2019 | - | -$21.95M(+20.7%) | -$101.33M(-2.0%) |
| Mar 2019 | - | -$27.68M(+4.0%) | -$99.31M(-5.9%) |
| Dec 2018 | -$92.92M(-15.0%) | -$28.84M(-26.3%) | -$93.77M(-12.1%) |
| Sep 2018 | - | -$22.84M(-14.6%) | -$83.65M(-3.8%) |
| Jun 2018 | - | -$19.94M(+10.0%) | -$80.58M(+5.2%) |
| Mar 2018 | - | -$22.15M(-18.3%) | -$85.03M(-2.0%) |
| Dec 2017 | -$80.83M | -$18.72M(+5.3%) | -$83.33M(-2.3%) |
| Sep 2017 | - | -$19.78M(+18.9%) | -$81.43M(-5.2%) |
| Jun 2017 | - | -$24.39M(-19.3%) | -$77.39M(-10.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2017 | - | -$20.45M(-21.6%) | -$70.10M(-4.1%) |
| Dec 2016 | -$67.27M(-168.1%) | -$16.82M(-6.9%) | -$67.37M(-33.1%) |
| Sep 2016 | - | -$15.74M(+7.9%) | -$50.63M(+7.1%) |
| Jun 2016 | - | -$17.09M(+3.5%) | -$54.47M(-14.0%) |
| Mar 2016 | - | -$17.72M(>-9900.0%) | -$47.80M(+1.4%) |
| Dec 2015 | -$25.09M(+57.5%) | -$79.00K(+99.6%) | -$48.50M(+25.8%) |
| Sep 2015 | - | -$19.58M(-87.9%) | -$65.41M(-22.9%) |
| Jun 2015 | - | -$10.42M(+43.4%) | -$53.24M(+11.3%) |
| Mar 2015 | - | -$18.42M(-8.5%) | -$60.03M(-2.4%) |
| Dec 2014 | -$59.11M(+16.9%) | -$16.98M(-129.1%) | -$58.63M(-2.4%) |
| Sep 2014 | - | -$7.41M(+56.9%) | -$57.24M(+16.3%) |
| Jun 2014 | - | -$17.21M(-1.1%) | -$68.42M(+2.0%) |
| Mar 2014 | - | -$17.02M(-9.2%) | -$69.81M(+2.9%) |
| Dec 2013 | -$71.17M(+18.7%) | -$15.59M(+16.1%) | -$71.89M(+5.9%) |
| Sep 2013 | - | -$18.59M(-0.0%) | -$76.39M(+2.9%) |
| Jun 2013 | - | -$18.59M(+2.7%) | -$78.68M(+2.8%) |
| Mar 2013 | - | -$19.11M(+4.8%) | -$80.92M(+5.8%) |
| Dec 2012 | -$87.54M(+15.3%) | -$20.09M(+3.9%) | -$85.89M(+1.3%) |
| Sep 2012 | - | -$20.89M(-0.3%) | -$86.98M(+2.5%) |
| Jun 2012 | - | -$20.83M(+13.5%) | -$89.19M(+0.8%) |
| Mar 2012 | - | -$24.08M(-13.7%) | -$89.92M(+9.5%) |
| Dec 2011 | -$103.30M(+23.5%) | -$21.18M(+8.3%) | -$99.34M(+12.3%) |
| Sep 2011 | - | -$23.10M(-7.1%) | -$113.29M(+12.5%) |
| Jun 2011 | - | -$21.57M(+35.6%) | -$129.45M(+23.2%) |
| Mar 2011 | - | -$33.50M(+4.6%) | -$168.57M(-2.6%) |
| Dec 2010 | -$135.07M(-60.9%) | -$35.13M(+10.5%) | -$164.30M(-5.7%) |
| Sep 2010 | - | -$39.25M(+35.3%) | -$155.39M(-10.7%) |
| Jun 2010 | - | -$60.69M(-107.7%) | -$140.37M(-76.2%) |
| Mar 2010 | - | -$29.22M(-11.4%) | -$79.68M(-57.9%) |
| Dec 2009 | -$83.97M(-100.8%) | -$26.23M(-8.2%) | -$50.46M(-108.2%) |
| Sep 2009 | - | -$24.24M | -$24.24M |
| Dec 2008 | -$41.82M(-91.7%) | - | - |
| Dec 2007 | -$21.81M | - | - |
FAQ
- What is Pacific Biosciences of California, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Pacific Biosciences of California, Inc.?
- What is Pacific Biosciences of California, Inc. annual EBITDA year-on-year change?
- What is the all-time high quarterly EBITDA for Pacific Biosciences of California, Inc.?
- What is the all-time high TTM EBITDA for Pacific Biosciences of California, Inc.?
What is Pacific Biosciences of California, Inc. annual EBITDA?
The current annual EBITDA of PACB is -$276.92M
What is the all-time high annual EBITDA for Pacific Biosciences of California, Inc.?
Pacific Biosciences of California, Inc. all-time high annual EBITDA is $38.97M
What is Pacific Biosciences of California, Inc. annual EBITDA year-on-year change?
Over the past year, PACB annual EBITDA has changed by +$365.00K (+0.13%)
What is the all-time high quarterly EBITDA for Pacific Biosciences of California, Inc.?
Pacific Biosciences of California, Inc. all-time high quarterly EBITDA is -$79.00K
What is the all-time high TTM EBITDA for Pacific Biosciences of California, Inc.?
Pacific Biosciences of California, Inc. all-time high TTM EBITDA is -$24.24M